Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
Zolmitriptan in the treatment of migraine attacks - the ARES study
Autore:
Sturzenegger, M; Daems, K; Billeter, M;
Indirizzi:
Univ Bern, Inselspital, Neurol Klin, CH-3010 Bern, Switzerland Univ Bern Bern Switzerland CH-3010 eurol Klin, CH-3010 Bern, Switzerland AstraZeneca, Zug, Switzerland AstraZeneca Zug SwitzerlandAstraZeneca, Zug, Switzerland
Titolo Testata:
SCHWEIZERISCHE MEDIZINISCHE WOCHENSCHRIFT
fascicolo: 51-52, volume: 130, anno: 2000,
pagine: 1984 - 1993
SICI:
0036-7672(200012)130:51-52<1984:ZITTOM>2.0.ZU;2-N
Fonte:
ISI
Lingua:
GER
Soggetto:
HEALTHY-VOLUNTEERS; RECEPTOR AGONIST; 311C90; ZOMIG(TM); TOLERABILITY;
Keywords:
migraine; triptans; zolmitriptan;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Clinical Medicine
Citazioni:
20
Recensione:
Indirizzi per estratti:
Indirizzo: Sturzenegger, M Univ Bern, Inselspital, Neurol Klin, CH-3010 Bern, Switzerland Univ Bern Bern Switzerland CH-3010 010 Bern, Switzerland
Citazione:
M. Sturzenegger et al., "Zolmitriptan in the treatment of migraine attacks - the ARES study", SCHW MED WO, 130(51-52), 2000, pp. 1984-1993

Abstract

In an open-label Swiss multicentre trial to assess patient acceptance, efficacy and safety of zolmitriptan 2.5 mg tablets in the acute treatment of migraine, 112 patients were enrolled and 281 migraine attacks evaluated. Patients completed a specially designed protocol during and after each attack. Special attention was given to the patients' subjective comparison of the study drug with previously used abortive treatments. On this matter, zolmitriptan per formed clearly better than analgesics and NSAIDS (78% "better"). Compared with sumatriptan, zolmitriptan was narrowly preferred (45% "better", 36% "worse"). Headache intensity was reduced from moderate or severe tomild or none after one hour in 51% and after 2 hours in 70%. Median time to efficacy was 50 minutes. Autonomic symp toms such as nausea and photo- and phonophobia were improved in 45 to 55%. A subjectively significant improvement in general condition (functionality) was reported in 51% after one hour and in 72% after 2 hours. Headache recurrence was reported by 25% of theresponders after a median time lapse of 14 hours. Adverse effects were reported by 22%, and were all short lasting and spontaneously reversible. Rapid efficacy, high and persistent response rate, improvement of headache, autonomic symptoms and general condition, and excellent tolerability are thus the reasons for the patients' preference of zolmitriptan over traditional abortive drugs.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 29/10/20 alle ore 22:55:25